Takeda and Sanofi join Milner Therapeutics Consortium

The Milner Therapeutics Institute are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month.

Now with 14 pharma partners and 3 academic partners, this is the largest cross-sector Biomedical Consortia in the UK that is working in target discovery across multiple disease areas and emerging technologies. Since 2015, the Consortium has initiated 37 research projects across the University of Cambridge, Babraham and Wellcome Sanger Institutes, bringing a research investment of  over £9m.

Sanofi has its UK R&D base on the Babraham Research Campus, south of Cambridge, which is focused on the discovery of novel therapeutics for the treatment of chronic inflammatory  and autoimmune diseases, and also brings expertise around antibody discovery and antibody engineering. Chris Schiering (Director of Translational Biology, Immune Regulation & Tolerance Cluster, I&I Research) and Mark Peakman (Head of Immune Regulation & Tolerance Cluster, I&I Research) will represent Sanofi on the Milner Innovation Board.

Takeda aims to discover and deliver life-transforming treatments in core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Takeda’s global Research and Development (R&D) center is based in Cambridge, Massachusetts with R&D Research Labs in San Diego, California, and Shonan, Japan and Regional R&D Centers and local sites across the globe. Peter Maycox (Director of External Innovation, Neuroscience Research) will represent Takeda on the Milner Innovation Board with an additional representative joining in the coming months.

 

More news and updates 

SiSaf’s bio-courier technology enables clinical trial success for topical treatment of mild to moderate Alopecia areata

SiSaf Ltd announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomised, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate (patchy) alopecia areata.

Manchester Met opens applications for September cohort of degree apprenticeships in science and sustainability

Employers looking for new talent or to upskill their current workforce can benefit from degree apprenticeships, starting Autumn 2024.

Discovery Park partners with Canterbury Christ Church University to open CoLab

Discovery Park, Kent’s thriving life science community, has opened the doors to CoLab, a new shared lab facility. In partnership with Canterbury Christ Church University, CoLab has been specially designed for early-stage life science businesses, providing flexible bench space in a collaborative coworking environment.

New blood test could prevent sudden child deaths caused by hereditary heart condition

A new blood test that could identify children with a potentially fatal heart condition has been developed by researchers at UCL (University College London) and Great Ormond Street Hospital (GOSH), thanks to investment from the charity Action Medical Research and self-funded not-for-profit, LifeArc.

Macomics announces appointment of Simon Dew as new Chief Business Officer

Macomics Ltd, a leader in macrophage drug discovery has announced the appointment of Simon Dew in the newly created position of Chief Business Officer (CBO). He will be instrumental in advancing Macomics’ mission to develop first-in-class medicines targeting macrophage-driven diseases of high unmet medical need, in oncology and chronic inflammatory diseases.

Bruntwood SciTech launches all new life science accelerator at Alderley Park

We’re delighted to announce the launch of the life science accelerator at Alderley Park, powered by Bruntwood SciTech and funded by the UK Government through the UK Shared Prosperity Fund. This initiative is designed to support early-stage life science companies across the UK, driving innovation and economic growth in the North West.

Biomanufacturing policy summit report 2024: policy pathways for biomanufacturing in Europe

This report summarises the summit’s main discussion points and takeaways and uses them as a foundation to build a strengths, weaknesses, opportunities and threats (SWOT) analysis for biomanufacturing in Europe.

Brandon Capital announces sixth fund with $270 million initial close to drive life science innovation

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at $270 million.

RSSL opens doors to innovation for the first time with exclusive behind-the-scenes event

RSSL, for the first time, will be opening their doors to not just clients. Providing a unique opportunity to the industry to delve into the science that drives innovation and see first hand what happens behind the scenes at RSSL.

Medannex unveils first-in-human study of novel cancer therapy at ASCO 2024

Medannex Ltd (Edinburgh) today revealed details of the attainment study at the American Society of Clinical Oncology (ASCO) annual meeting. The phase 1b oncology study is the first clinical evaluation of a therapy targeting annexin-A1, a new and unique cancer target.

 

More within